Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.

BACKGROUND AND PURPOSE

We sought to understand why (-)-cannabidiol (CBD) and (-)-cannabidiol-dimethylheptyl (CBD-DMH) exhibit distinct pharmacology, despite near identical structures.

EXPERIMENTAL APPROACH

HEK293A cells expressing either human type 1 cannabinoid (CB ) receptors or CB receptors were treated with CBD or CBD-DMH with or without the CB and CB receptor agonist CP55,940, CB receptor allosteric modulator Org27569 or CB receptor inverse agonist SR144528. Ligand binding, cAMP levels and βarrestin1 recruitment were measured. CBD and CBD-DMH binding was simulated with models of human CB or CB receptors, based on the recently published crystal structures of agonist-bound (5XRA) or antagonist-bound (5TGZ) human CB receptors.

KEY RESULTS

At CB receptors, CBD was a negative allosteric modulator (NAM), and CBD-DMH was a mixed agonist/positive allosteric modulator. CBD and Org27569 shared multiple interacting residues in the antagonist-bound model of CB receptors (5TGZ) but shared a binding site with CP55,940 in the agonist-bound model of CB receptors (5XRA). The binding site for CBD-DMH in the CB receptor models overlapped with CP55,940 and Org27569. At CB receptors, CBD was a partial agonist, and CBD-DMH was a positive allosteric modulator of cAMP modulation but a NAM of βarrestin1 recruitment. CBD, CP55,940 and SR144528 shared a binding site in the CB receptor models that was separate from CBD-DMH.

CONCLUSION AND IMPLICATIONS

The pharmacological activity of CBD and CBD-DMH in HEK293A cells and their modelled binding sites at CB and CB receptors may explain their in vivo effects and illuminates the difficulties associated with the development of allosteric modulators for CB and CB receptors.

LINKED ARTICLES

This article is part of a themed section on 8 European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.

© 2018 The British Pharmacological Society.